SEC Company Response from PALISADE BIO, INC. (PALI) (CIK 0001357459) (PALI) — Mar 30, 2020
PALISADE BIO, INC. (PALI) (CIK 0001357459)
Date: March 30, 2020 · CIK: 0001357459 · Accession: 0001171843-20-002161
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236543
Letter
Division of Corporate Finance United States Securities and Exchange Commission Registration Statement on Form S-3 Filed February 20, 2020 File No. 333-236543
RE: Seneca Biopharma, Inc.
Dear Ladies and Gentlemen:
We have been informed telephonically that the Staff has no additional comments to the above referenced registration statement. Accordingly, Seneca Biopharma, Inc. (“Company”) is requesting that the above referenced registration statement be declared effective at 4:00 p.m. Eastern Time, on Tuesday, March 31, 2020 or as soon as practicable thereafter.
In connection with this acceleration request, we hereby acknowledge that:
1. should the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, such action will not foreclose the Commission from taking any action with respect to the filing;
2. the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, will not relieve the Issuer from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
3. the Issuer may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should you require additional information, feel free to contact the undersigned.
Sincerely,
Seneca Biopharma, Inc.
Show Raw Text
CORRESP
1
filename1.htm
SENECA BIOPHARMA, INC.
March 30, 2020
Tim Buchmiller
Staff Attorney
Division of Corporate Finance
United States Securities and Exchange Commission
Washington, DC 20549
RE: Seneca Biopharma, Inc.
Registration Statement on Form S-3
Filed February 20, 2020
File No. 333-236543
Dear Ladies and Gentlemen:
We have been informed telephonically that the Staff has no additional
comments to the above referenced registration statement. Accordingly, Seneca Biopharma, Inc. (“Company”) is requesting
that the above referenced registration statement be declared effective at 4:00 p.m. Eastern Time, on Tuesday, March 31, 2020 or
as soon as practicable thereafter.
In connection with this acceleration request, we hereby acknowledge that:
1. should the Commission or the staff, acting
pursuant to delegated authority, in declaring the filing effective, such action will not foreclose the Commission from taking any
action with respect to the filing;
2. the action of the Commission or the staff,
acting pursuant to delegated authority, in declaring the filing effective, will not relieve the Issuer from its full responsibility
for the adequacy and accuracy of the disclosure in the filing; and
3. the Issuer may not assert staff comments and the declaration of effectiveness as a
defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should you require additional information, feel free to contact the undersigned.
Sincerely,
Seneca Biopharma, Inc.
/s/ Kenneth Carter
Kenneth Carter
Executive Chairman